,8 Besides these RCTs, there is limited evidence from large-scale RCTs or real-world settings on the effectiveness of GLP-1 agonists and DPP-4 inhibitors compared to each other or sulfonylureas, the most commonly used second-line antihyperglycemic class, in dementia risk among patients with T2DM. The gene discussed is DPP4; the disease is dementia.